Literature DB >> 25667273

Gauging the Long-Term Benefits of Ipilimumab in Melanoma.

Antoni Ribas1, Keith T Flaherty2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25667273     DOI： 10.1200/JCO.2014.59.5041

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

Review 1.  Metastatic melanoma and immunotherapy.

Authors:  Benjamin Herzberg; David E Fisher
Journal:  Clin Immunol       Date:  2016-07-16       Impact factor: 3.969

Review 2.  Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors:  Francesca Maria Bosisio; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-01-05       Impact factor: 4.064

Review 3.  The role of tumor microenvironment in melanoma therapy resistance.

Authors:  Rajasekharan Somasundaram; Meenhard Herlyn; Stephan N Wagner
Journal:  Melanoma Manag       Date:  2016-02-12

4.  Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing.

Authors:  Francesca Maria Bosisio; Asier Antoranz; Yannick van Herck; Maddalena Maria Bolognesi; Lukas Marcelis; Clizia Chinello; Jasper Wouters; Fulvio Magni; Leonidas Alexopoulos; Marguerite Stas; Veerle Boecxstaens; Oliver Bechter; Giorgio Cattoretti; Joost van den Oord
Journal:  Elife       Date:  2020-02-14       Impact factor: 8.140

5.  Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors.

Authors:  Patrick A Ott; Catherine J Wu
Journal:  Cancer Discov       Date:  2019-03-12       Impact factor: 39.397

Review 6.  Nivolumab in combination with ipilimumab for the treatment of melanoma.

Authors:  Rajasekharan Somasundaram; Meenhard Herlyn
Journal:  Expert Rev Anticancer Ther       Date:  2015       Impact factor: 4.512

7.  Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.

Authors:  Jeremy D Waight; Dhan Chand; Sylvia Dietrich; Randi Gombos; Thomas Horn; Ana M Gonzalez; Mariana Manrique; Lukasz Swiech; Benjamin Morin; Christine Brittsan; Antoine Tanne; Belinda Akpeng; Ben A Croker; Jennifer S Buell; Robert Stein; David A Savitsky; Nicholas S Wilson
Journal:  Cancer Cell       Date:  2018-06-11       Impact factor: 31.743

8.  Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?

Authors:  Christiane Margue; Susanne Reinsbach; Demetra Philippidou; Nicolas Beaume; Casandra Walters; Jochen G Schneider; Dorothée Nashan; Iris Behrmann; Stephanie Kreis
Journal:  Oncotarget       Date:  2015-05-20

9.  Long-lasting multifunctional CD8+ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Authors:  Florian Wimmers; Erik H J G Aarntzen; Tjitske Duiveman-deBoer; Carl G Figdor; Joannes F M Jacobs; Jurjen Tel; I Jolanda M de Vries
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

10.  Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy.

Authors:  J D Nosanchuk; A Jeyakumar; A Ray; E Revskaya; Z Jiang; R A Bryan; K J H Allen; R Jiao; M E Malo; B L Gómez; A Morgenstern; F Bruchertseifer; D Rickles; G B Thornton; A Bowen; A Casadevall; E Dadachova
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.